Free Newsletter
SPOTLIGHT: Thailand skirts Plavix patent
Thailand's health ministry has decided to import a generic version of the heart drug Plavix from India, even though the Schering Plough drug is still under patent. Made by M-Cure, the pills will be imported using compulsory licensing, a World Trade Organization waiver that allows developing nations to bypass drug patents when they have no means to pay for branded versions of necessary drugs. Previously, the Thai government had invoked compulsory licensing for two anti-HIV agents. E.U. and U.S. officials protested the Plavix decision. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: